Citi believes today’s weakness in Arcellx (ACLX) is “an overreaction to the highly preliminary” Phase 1 inMMyCAR data for Kelonia Therapeutics’ KLN-1010. While the achievement of MRD-negativity is a positive early signal, the study featured just three patients and a maximum of three months’ follow-up, “leaving critical questions about response durability entirely unanswered,” according to the firm, which would be buyers on the weakness. Citi maintains a Buy rating and $110 price target on Arcellx shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx weakness on competitive worries ‘overdone,’ says Guggenheim
- Arcellx Inc’s Strategic Advantage in Gilead Partnership Drives Buy Rating and $130 Price Target
- Arcellx initiated with a Peer Perform at Wolfe Research
- Arcellx Inc.: Promising Developments and Strategic Positioning Drive Buy Rating
- Arcellx, Inc. Reports Increased Loss Amid Rising Expenses